Menu
Close
Home
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Latest Development
Company News
Investor Relations
Information Disclosure
Presentations
Corporate Governance
Investor Calendar
IR Contact
Join Us
Contact Us
Global
CN
TC
Home
CN
TC
About ImmuneOnco
About Us
Core Team
Development Strategy
ESG Report
Scientific Technology and R&D
Technology Platform
Product Pipeline
Scientific News
Company News
Investor Relations
Information Disclosure
Corporate Governance
Investor Calendar
Presentation Materials
Stock Information
Analyst Coverage
IR Contact
Email Subscription Center
Join Us
Contact Us
>
×
Investor Relations
Information Disclosure
Announcements and Circulars
Analyst Report
Financial Reports
Listing Documents
Year
2026
2025
2024
2023
Month
12
11
10
09
08
07
06
05
04
03
02
01
2026-09-04
Next Day Disclosure Return
2026-09-04
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August, 2026
2026-08-28
(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
2026-08-28
(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
2026-08-27
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M FOR FIRST-LINE TREATMENT OF ADVANCED HCC
2026-08-27
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M FOR FIRST-LINE TREATMENT OF ADVANCED HCC
2026-08-26
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
2026-08-26
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
2026-08-25
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PAH TRIAL AND COMPLETION OF ENROLMENT FOR SAD AND MAD COHORTS FOR IMC-003
2026-08-25
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PAH TRIAL AND COMPLETION OF ENROLMENT FOR SAD AND MAD COHORTS FOR IMC-003
2026-08-21
VOLUNTARY ANNOUNCEMENT - APPROVAL OF IND APPLICATION OF IMM0306 FOR PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY THE FDA
2026-08-21
VOLUNTARY ANNOUNCEMENT - APPROVAL OF IND APPLICATION OF IMM0306 FOR PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY THE FDA
2026-08-14
DATE OF BOARD MEETING
2026-08-07
VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE CAPITAL INCREASE OF A SUBSIDIARY
2026-08-06
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July, 2026
2026-07-31
SUPPLEMENTAL ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY
2026-07-24
Next Day Disclosure Return
2026-07-23
Next Day Disclosure Return
2026-07-22
Next Day Disclosure Return
2026-07-17
Next Day Disclosure Return
总计 233
1
2
3
4
5
6
7
8
...
11
12